Axsome Therapeutics Inc - ESG Rating & Company Profile powered by AI
Browse to the end of the webpage for potential risks for Axsome Therapeutics Inc based on industry, location and marketcap. This analysis of Axsome Therapeutics Inc uses data from across the web and also from available filings by Axsome Therapeutics Inc. Comprehensive Sustainability assessment of Axsome Therapeutics Inc can be reached by logging in.
Axsome Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.0; made up of an environmental score of 2.0, social score of 8.0 and governance score of 8.0.
6.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 483 | Wakamoto Pharmaceutical Co Ltd | 6.1 | High |
| 483 | aTyr Pharma Inc | 6.1 | High |
| 498 | Axsome Therapeutics Inc | 6.0 | High |
| 498 | Cann Group Ltd | 6.0 | High |
| 498 | Biosynex SA | 6.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Axsome Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Axsome Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Axsome Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Axsome Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Axsome Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Axsome Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Axsome Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Axsome Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Axsome Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Axsome Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Axsome Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Axsome Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Axsome Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Axsome Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Axsome Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Axsome Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Axsome Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Axsome Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.